Treatment outcomes of radiotherapy for anaplastic thyroid cancer |
Park, Jong Won
(Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)
Choi, Seo Hee (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) Yoon, Hong In (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) Lee, Jeongshim (Department of Radiation Oncology, Inha University Hospital) Kim, Tae Hyung (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) Kim, Jun Won (Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine) Lee, Ik Jae (Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine) |
1 | Glaser SM, Mandish SF, Gill BS, Balasubramani GK, Clump DA, Beriwal S. Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall survival. Head Neck 2016;38 Suppl 1:E2083-90. DOI |
2 | Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011;21:25-30. DOI |
3 | Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335-42. DOI |
4 | Busnardo B, Daniele O, Pelizzo MR, et al. A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Invest 2000;23:755-61. DOI |
5 | McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 200;130:1028-34. |
6 | Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999;84:4043-9. DOI |
7 | Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 2010;22:486-97. DOI |
8 | Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-64. DOI |
9 | Zivaljevic V, Tausanovic K, Paunovic I, et al. Age as a prognostic factor in anaplastic thyroid cancer. Int J Endocrinol 2014;2014:240513. |
10 | Kwon J, Kim BH, Jung HW, Besic N, Sugitani I, Wu HG. The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and meta-analysis. Eur J Cancer 2016;59:34-45. DOI |
11 | Sykorova V, Dvorakova S, Vcelak J, et al. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing. Anticancer Res 2015;35:2029-36. |
12 | Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer staging manual. 7th ed. New York, NY: Springer;2010. |
13 | Lim SM, Shin SJ, Chung WY, et al. Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J 2012;53:352-7. DOI |
14 | Wein RO, Weber RS. Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg 2011;19:113-8. DOI |
15 | Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011;21:1183-9. DOI |
16 | Derbel O, Limem S, Segura-Ferlay C, et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 2011;11:469. DOI |
17 | He X, Li D, Hu C, Wang Z, Ying H, Wu Y. Outcome after intensity modulated radiotherapy for anaplastic thyroid carcinoma. BMC Cancer 2014;14:235. DOI |
18 | Ito K, Hanamura T, Murayama K, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck 2012;34:230-7. DOI |
19 | Yau T, Lo CY, Epstein RJ, Lam AK, Wan KY, Lang BH. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol 2008;15:2500-5. DOI |
20 | McLarnon A. Thyroid cancer: pazopanib alone is not effective against anaplastic thyroid cancer. Nat Rev Endocrinol 2012;8:565. |
21 | National Comprehensive Cancer Network. NCCN Guidelines -thyroid carcinoma [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2018 [cited 2018 Jun 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ thyroid.pdf. |
22 | Veness MJ, Porter GS, Morgan GJ. Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ J Surg 2004;74:559-62. DOI |
23 | Kasmann L, Bolm L, Janssen S, Rades D. Prognostic factors for survival in patients treated with multimodal therapy for anaplastic thyroid cancer. Anticancer Res 2016;36:4697-700. DOI |
24 | Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma: treatment outcome in 75 patients. Radiother Oncol 2009;92:100-4. DOI |
25 | Goutsouliak V, Hay JH. Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol (R Coll Radiol) 2005;17:75-8. DOI |
![]() |